Samsung Biologics Reports Second Quarter 2026 Financial Results
Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion Delivered stable business performance through continued disciplined execution Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026...
Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion Delivered stable business performance through continued disciplined execution Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.